Acquisition of generic injectable drug business

Hikma Pharmaceuticals

Our attorneys represented Hikma Pharmaceuticals $300 million acquisition of the Bedford generic injectable drug business from Boehringer Ingelheim. Regarding the transaction, Said Darwazah, Chief Executive Officer of Hikma commented: “Bedford’s impressive product portfolio and deep pipeline will significantly increase the scale and scope of our rapidly growing US Injectables business. The large number of high value, niche and differentiated products we are acquiring will strengthen our market position in the US and will benefit patients by bringing back products to the market that are currently in short supply.”

Email Disclaimer